Systemic SclerosisPhase 2DISTOL-1NCT00775463
Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine
A Phase 2 study testing treprostinil diethanolamine in people with Systemic Sclerosis and Scleroderma, run by United Therapeutics at 30 sites in 3 countries.
Trial summary
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Systemic Sclerosis, Scleroderma
- What is being tested?
- treprostinil diethanolamine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 148 participants
- Where
- 30 sitesin 3 countries
- Study dates
- May 2009to Jul 2011
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject gave voluntary written informed consent to participate in the study
- Diagnosis of systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria
- Males and females age greater than 18 years at Screening
- Presence of at least one active digital ulcer (met protocol defined qualifications for active digital ulcer) at Baseline
- Females of childbearing potential willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test at Screening and Baseline
- Able to communicate effectively with study personnel and willing to comply with protocol requirements
Who cannot join
- Diagnosis of pulmonary arterial hypertension (PAH)
- Body weight less than 40 kg at Screening and confirmed at Baseline
- History of postural hypotension, unexplained syncope, a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening and Baseline
- Hemoglobin concentration less than 75% of the lower limit of the normal range at Screening
- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C, or ALT greater than three times upper limit of normal
- Intractable diarrhea, or severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening; any severe organ failure (e.g., lung, kidney), bleeding diathesis or platelet disorder, or any life-threatening condition
Show all 19Show fewer
- Pregnant or breast-feeding
- Simultaneously fulfilled criteria for a second connective tissue disease including systemic lupus erythermatosus, rheumatoid arthritis or inflammatory myopathy
- Sympathectomy of the upper limb, involving the hand, performed within 12 months of Baseline. Sympathectomy performed on the non-target limb (hand not presenting with qualifying ulcers) or which did not include the hand, performed within 6 months of Baseline
- Receipt of prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months of Baseline for conditions including Raynaud's phenomenon, rest pain and / or digital ulcers
- Required systemic antibiotics for infected digital ulcers within 2 weeks of Screening
- Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline
- Treatment with endothelin receptor antagonists within 1 month prior to Baseline
- Patients on phosphodiasterase inhibitors, such as sildenafil or tadalafil, who have received treatment for less than 6 months prior to Baseline (unless for intermittent treatment of male erectile dysfunction)
- Treatment with statin within 1 month prior to Screening, unless for management of hyperlipidemia
- Received an investigational product within 1 month preceding Screening
- Known hypersensitivity to treprostinil diethanolamine or any of the excipients
- Tobacco or nicotine use at any level within the past 6 months prior to Screening
- Any condition or laboratory that in the opinion of the investigator might interfere with subject's participation, pose an additional risk for the subject, could prevent understanding the objectives, nature or consequences of the trial, compliance with the protocol, adherence to therapy, or that would interfere with interpretation of study assessments
Trial locations and contacts
30 sites in 3 countries.
30 sites in 3 countries
United States24 sites
University of Michigan Scleroderma Program
Ann Arbor, Michigan, 48106
Denver Medical Center
Aurora, Colorado, 80045
Johns Hopkins University - Division of Rheumatology
Baltimore, Maryland, 21224
University of Alabama - Arthritis Clinical Intervention Program
Birmingham, Alabama, 35294
Boston University School of Medicine
Boston, Massachusetts, 02118
Medical University of South Carolina
Charleston, South Carolina, 29425
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, 60611
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
University of Connecticut Health Center
Farmington, Connecticut, 06030
University of Texas - Houston
Houston, Texas, 77030
University of Indiana School of Medicine
Indianapolis, Indiana, 46202
North Shore-LIJ Health System
Lake Success, New York, 11042
UCLA
Los Angeles, California, 90095
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
University of Minnesota
Minneapolis, Minnesota, 55455
UMDNJ Clinical Research Center
New Brunswick, New Jersey, 08903
The Hospital for Special Surgery
New York, New York, 10021
Stanford University School of Medicine/Palo Alto VA Health Care System
Palo Alto, California, 94304
University of Pittsburgh
Pittsburgh, Pennsylvania, 15261
University of Utah
Salt Lake City, Utah, 84132
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259
Virginia Mason Medical Center
Seattle, Washington, 98111
University of Toledo
Toledo, Ohio, 43614
Georgetown University
Washington D.C., District of Columbia, 20007
Canada3 sites
Dalhousie University - QEII Health Science Center
Halifax, Nova Scotia, B3H4K4
St Joseph's Health Care
London, Ontario, N6A4V2
McGill University
Montreal, Quebec, H3T1E2
United Kingdom3 sites
Clinical Sciences Center - University Hospital
Liverpool, L9 7AL
Royal Free Hospital - Center for Rheumatology
London, NW32QG
Salford Royal Hospital
Manchester, M139PT
About this study
Official title: DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.
- Conditions
- Systemic Sclerosis, Scleroderma
- Being tested
- treprostinil diethanolamine, placebo
- Keywords
- Scleroderma, Diffuse, Scleroderma, Limited, Scleroderma, Systemic, Ulcer, prostacyclin
- Medical subject headings
- Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Ulcer
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
treprostinil diethanolamineDrug
oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
placeboDrug
| Study group | Role | What they receive |
|---|---|---|
| treprostinil diethanolamine | Experimental | Treprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose. Receives: Drug: treprostinil diethanolamine |
| placebo (sugar pill) | Placebo comparator | Matching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose. Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Net Ulcer Burden
Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.
Measured: Week 20
Secondary outcomes (11)
Digital Ulcer Pain VAS
Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.
Measured: Week 20
Patient Global Assessment of Digital Ulcer Severity VAS
Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease).
The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
Measured: Week 20
Physician Global Assessment of Digital Ulcer Severity VAS
Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease).
The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.
Measured: Week 20
Cochin Hand Function Scale (CHFS)
The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.
Measured: Week 20
Scleroderma Health Assessment Questionnaire (SHAQ)
The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).
Measured: Week 20
Modified Rodnan Skin Score (mRSS)
The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .
Measured: Week 20
Short-Form McGill Pain Questionnaire
The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).
Measured: Week 20
Patient Impression of Change (PIC) Questionnaire
The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).
Measured: Week 20
Short Form 36
Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.
Measured: Week 20
Time to Ulcer Healing- Percentage of Subjects With Complete Healing
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.
Measured: Week 20
Time to Ulcer Healing
A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.
Measured: Week 20
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2008 (estimated)
- Study startMay 2009
- Primary completionMar 2011
- Study completionJul 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Systemic SclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 148 participants (actual)
Sponsor and investigators
- Lead sponsor
- United Therapeutics
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- James Seibold, MD, Principal investigator, Scleroderma Research Consultants LLC, Avon, CT,
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00775463
- Sponsor's protocol ID
- TDE-DU-201
- Acronym
- DISTOL-1
- Status last verified
- Dec 2023
- First submitted
- 17 Oct 2008
- Last updated
- 28 Dec 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Publications
Mecoli CA, Perin J, Van Eyk JE, Zhu J, Fu Q, Allmon AG, Rao Y, Zeger S, Wigley FM, Hummers LK, Shah AA. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). Clin Rheumatol. 2020 Apr;39(4):1199-1205. doi: 10.1007/s10067-019-04863-0. Epub 2019 Dec 19.
PubMed 31858338
Study at a glance
From the registry record, last updated by the sponsor on 28 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study
- ClinicalTrials.gov ID
- NCT00775463
- Acronym / sponsor ID
- DISTOL-1 / TDE-DU-201
- Conditions
- Systemic Sclerosis, Scleroderma
- Keywords
- Scleroderma, Diffuse, Scleroderma, Limited, Scleroderma, Systemic, Ulcer, prostacyclin
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 148 participants (actual)
- Lead sponsor
- United TherapeuticsIndustry (pharma, biotech, devices)
- Study start
- May 2009
- Primary completion
- Mar 2011 (actual)
- Study completion
- Jul 2011 (actual)
- First posted
- 20 Oct 2008 (estimated)
- Results
- Posted 17 Mar 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| treprostinil diethanolamine | Experimental | Drug: treprostinil diethanolamineTreprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose. |
| placebo (sugar pill) | Placebo comparator | Drug: placeboMatching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Subject gave voluntary written informed consent to participate in the study
- Diagnosis of systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria
- Males and females age greater than 18 years at Screening
- Presence of at least one active digital ulcer (met protocol defined qualifications for active digital ulcer) at Baseline
- Females of childbearing potential willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test at Screening and Baseline
Key exclusion criteria (19 listed)
- Diagnosis of pulmonary arterial hypertension (PAH)
- Body weight less than 40 kg at Screening and confirmed at Baseline
- History of postural hypotension, unexplained syncope, a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening and Baseline
- Hemoglobin concentration less than 75% of the lower limit of the normal range at Screening
- Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C, or ALT greater than three times upper limit of normal
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| treprostinil diethanolamineoral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID) | Drug | treprostinil diethanolamine |
| placebo | Drug | placebo (sugar pill) |
Primary outcome
Net Ulcer Burden
Time frame: Week 20
Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.
11 secondary outcomes
Digital Ulcer Pain VAS
Time frame: Week 20
Patient Global Assessment of Digital Ulcer Severity VAS
Time frame: Week 20
Physician Global Assessment of Digital Ulcer Severity VAS
Time frame: Week 20
Cochin Hand Function Scale (CHFS)
Time frame: Week 20
Scleroderma Health Assessment Questionnaire (SHAQ)
Time frame: Week 20
Modified Rodnan Skin Score (mRSS)
Time frame: Week 20
Short-Form McGill Pain Questionnaire
Time frame: Week 20
Patient Impression of Change (PIC) Questionnaire
Time frame: Week 20
Short Form 36
Time frame: Week 20
Time to Ulcer Healing- Percentage of Subjects With Complete Healing
Time frame: Week 20
Time to Ulcer Healing
Time frame: Week 20
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Dec 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31858338Mecoli CA, Perin J, Van Eyk JE, Zhu J, Fu Q, Allmon AG, Rao Y, Zeger S, Wigley FM, Hummers LK, Shah AA. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). Clin Rheumatol. 2020 Apr;39(4):1199-1205. doi: 10.1007/s10067-019-04863-0. Epub 2019 Dec 19.
Related trials for Systemic Sclerosis
Not yet recruitingPhase 2
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
Scleroderma, Sclerodactyly
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
Systemic Sclerosis (SSc), Calcinosis Cutis
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
James Seibold, MD principal investigator
Scleroderma Research Consultants LLC, Avon, CT,
30 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing treprostinil diethanolamine in people with Systemic Sclerosis and Scleroderma, run by United Therapeutics at 30 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 30 sites in United States, Canada, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 17 Mar 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Net Ulcer Burden (time frame: Week 20). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00775463, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2023.